D-dimer in Hospitalized Patients
Download
Report
Transcript D-dimer in Hospitalized Patients
The Clinical Utility of
D-dimer Assays
Beth Phillips MT,SH (ASCP)
Zone Technical Application Specialist
Siemens Healthcare Diagnostics
© Siemens 2013. All rights reserved.
Objectives:
Define VTE as DVT and PE
Identify D-dimer assays and the role they play in DVT/PE
Explain Well’s pre-test probability scoring and clinical models
Describe evaluation of D-dimer assay results
Page 2
© Siemens 2013. All rights reserved.
History of Fibrinolysis
4th Century BC…Hippocratic school familiar with blood fluidity
1687 (300 years later) Malpighi noted blood clotted & reliquidfied after death
1893 Dastre coined term “fibrinolysis”
1905 Morawitz concluded process was probably enzymatic
1959 Sherry proved fibrinolysis due to activator converting plasminogen to
plasmin
1960 five fragments of fibrinogen when treated with plasmin: A, B, C, D, & E
1983 Greenberg measured “fibrin d-dimer” to differential FDP derived from
fibrinogen or fibrin
Page 3
© Siemens 2013. All rights reserved.
Use of D-Dimer
30 years ago proposed as aid in suspect DVT
mid 1990’s focus on use as aid in ruling out VTE
DIC profile
Page 4
© Siemens 2013. All rights reserved.
Venous Thromboembolism Epidemiology
Yearly in the USA:
> 600,000 Deep Vein Thrombosis
~ 150,000 Pulmonary Embolism
Diagnostic Challenges with DVT/PE
90% of PE develop from DVT
PE mortality 18%-30% without treatment
VTE suspected…..15% - 25% actually positive
Clinical suspicion has increased
Prevalence has decreased, some statistics state only 10% of suspected
VTE are positive
Page 5
© Siemens 2013. All rights reserved.
VENOUS THROMBOEMBOLISM
Venous Thromboembolic Disease
DVT
PE
Distinct clinical entities
Manifestation of the same disease
Venous Blood Clot
Page 6
Embolus
© Siemens 2013. All rights reserved.
VENOUS THROMBOEMBOLISM
DVT-- thrombi form in deep veins of legs, pelvis or upper extremities
PE -- thrombi embolize to pulmonary arteries
elevate pulmonary vascular resistance
heart failure
cardiogenic shock
impairment of gas exchange
Page 7
© Siemens 2013. All rights reserved.
Deep Vein Thrombosis (DVT)
DVT may occur without obvious symptoms and may be difficult to detect
Up to 50% of DVT incidents may produce minimal symptoms or are
completely "silent”
85% are in the proximal venous system and 15% limited to the calf
20% to 30% of calf thrombi extend proximally
Symptoms:
• Pain, tenderness, or sudden swelling in the leg
• Discoloration or visibly large veins
• Skin that is warm to the touch
Page 8
© Siemens 2013. All rights reserved.
Pulmonary Embolism (PE)
The highest incidence of recognized pulmonary embolism occurs in
hospitalized patients
Approximately 10% of patients with diagnosed pulmonary embolism die within
the first 60 minutes
Symptoms:
•
•
•
•
•
•
•
•
Page 9
Shortness of breath
Anxiety or nervousness
Rapid pulse
Excessive sweating
Sharp chest pain
Cough that may produce a bloody discharge
Very low blood pressure
Fainting
© Siemens 2013. All rights reserved.
WHY IDENTIFY PATIENTS WITH VTE
Prevent mortality and morbidity associated with PE
Anticoagulant therapy reduces risk of fatal outcome 15 fold
Anticoagulant therapy related to high mortality and morbidity
Justification for risk of bleeding
Cost savings
Page 10
© Siemens 2013. All rights reserved.
VTE Disease Predisposing Risk Factors
Clinical conditions
Environment
surgery, trauma, cancer
air travel
hormonal influences
smoking
age
Hereditary coagulapathies
Factor V Leiden
Protein C / S Deficiency
AT Deficiency
Prothrombin Gene Mutation
Acquired coagulapathies
Lupus Anticoagulant
Page 11
© Siemens 2013. All rights reserved.
Diagnostic Challenges with DVT/PE
Only 15-25% of suspected VTE patients have disease
DVT mortality rate of 21% in elderly
PE mortality rate 30% without treatment
90% of PE develops from DVT
PE causes more deaths annually in the U.S. than
breast cancer, highway fatalities and AIDS combined
Page 12
© Siemens 2013. All rights reserved.
DIAGNOSING DVT/PE
History and Exam
Determines
Clinical Probability
Low
Moderate
High
Diagnostic Studies
Page 13
© Siemens 2013. All rights reserved.
D-Dimer + Probability Score
“…DD testing has gained wide acceptance for ruling out the disease, at least in the
outpatient population referred to the emergency department.”
“…ELISA DD assays and automated latex turbidimetric tests are associated with the
highest sensitivity and with virtually no interobserver variability.”
“…these tests should be used to rule out VTE only in non-high clinical probability
patients.”
D-Dimer for venous thromboembolism diagnosis: 20 years later; M. Righini, A. Perrier, P. De Mperloose amnd H. Bpima,eaix
Journal of Thrombosis and Haemostasis, 2008, 6: 1059-1071
Page 14
© Siemens 2013. All rights reserved.
Wells Pre-test Probability of DVT
Clinical Parameter Score
Score
Active cancer (treatment ongoing, or within 6 months or palliative)
+1
Paralysis or recent plaster immobilization of the lower extremities
+1
Recently bedridden for >3 d or major surgery <4 wk
+1
Localized tenderness along the distribution of the deep venous system
+1
Entire leg swelling
+1
Calf swelling >3 cm compared to the asymptomatic leg
+1
Pitting edema (greater in the symptomatic leg)
+1
Score
Previous DVT documented
+1
>3
High probability
Collateral superficial veins (nonvaricose)
1 or 2
Moderate probability
+1
Alternative diagnosis (as likely or > that of DVT)
<0
Low probability
-2
Page 15
© Siemens 2013. All rights reserved.
Wells Pre-Test Probability of PE
Clinical Parameter Score
Suspected DVT
Alternate Dx is less likely than PE
Heart rate >100
Immobilized or surgery in last 4 wk
Previous DVT/PE
Hemoptysis
Malignancy (treated within 6 mo.)
Score
3.0
3.0
1.5
1.5
1.5
1.0
1.0
Score
Probability
Risk
0–2
3–6
>6
Low
Moderate
High
3.6%
20.5%
66.7%
Wells, PS et al. Thromb Haemost. 83: 416, 2000
Page 16
© Siemens 2013. All rights reserved.
Implication of D-dimer
Thrombin
Fibrinogen
Soluble Fibrin + FP A+B
Plasminogen Activators
(tissue PA, urokinase PA, FXII, etc)
FXIII
Fibrin Clot
DED
Plasmin
Plasminogen
D-dimer
D=D
Clot + Fibrinolysis = D-dimer formation
No Clot + Fibrinolysis = D-dimer formation
Page 17
© Siemens 2013. All rights reserved.
Elevated D-dimer
DIC
Age
Fibrinolytic therapy within 7 days
Hospitalized patients in general
Malignancies
Stress
Aortic aneurysm, MI
Excessive exercise
Sepsis, severe infection, pneumonia
Lipemic samples
Trauma, surgery
Hemolyzed samples
Liver cirrhosis
Pregnancy or obstetric complication
Page 18
© Siemens 2013. All rights reserved.
Why Differences in D-dimer Assays
No D-dimer assay produces identical results to another D-dimer assay
D-dimer antigen is not homogenous but a mixture of fragments & compounds
containing fragments of D & E of different molecular weight (HMW & LMW)
D-dimer assays use different antibodies, buffers, measuring technique, standards
Page 19
© Siemens 2013. All rights reserved.
Comparability of D-Dimer Assays
Facts that effect assay comparability
No international standard for D-dimer
Different reporting units: D-dimer units (DDU) & Fibrinogen Equivalent Units (FEU)
Antibodies have different affinity to D-dimer compounds
Different reagents & assay methodologies result in different interferences
and signals
Conclusions
Each manufacturer establishes its own standardization method
Various assays have different performance characteristics
Different standardizations typically result in different quantitative results
on the same patient
Page 20
© Siemens 2013. All rights reserved.
Goals of Diagnostic Studies
Provide reliable diagnosis
Shortest possible time
Least discomfort to patient
Reasonable cost
Page 21
© Siemens 2013. All rights reserved.
PE / DVT Exclusion
D-dimer
Testing Algorithms
Page 22
© Siemens 2013. All rights reserved.
Algorithm for PE
Low Clinical Probability of embolism
Highly sensitive D-dimer assay
Negative
Diagnosis ruled out
Positive
Ventilation-perfusion
scan or CT scan
. Fedullo, P, Tapson, V. The Evaluation of Suspected Pulmonary Embolism. N Engl J Med 2003:1247-56.
Page 23
© Siemens 2013. All rights reserved.
Algorithm for DVT
Hirsh J, Lee AY How We Diagnose & Treat Deep Vein Thrombosis, Blood 2002; 99(9): 3102-3110
Page 24
© Siemens 2013. All rights reserved.
Evaluating
D-dimer Results
Page 25
© Siemens 2013. All rights reserved.
D-dimer vs. Imaging…Why Results Do Not Agree
Questions to Ask:
Age of Clot
Patient Age
Time of Initial Symptoms
Cancer
Size of Clot
Previous Thrombosis
Where Clot Located
Pregnant
Anticoagulants before Draw
In-patient
Page 26
© Siemens 2013. All rights reserved.
Normal D-dimer with Abnormal Scan
Distal DVT
Subsegmental / peripheral PE
Presentation to ER > 7days after symptoms
Size of clot, small clot may produce minimal D-dimer levels
Anticoagulant therapy within 24 hours
Page 27
© Siemens 2013. All rights reserved.
D-dimer vs. Imaging…Why Results Do Not Agree
Age of Thrombus
Patients who report greater than 14 days duration of symptoms demonstrate
inactive fibrinolysis and D-dimer levels rapidly decrease, false negative
Size of Thrombus
Smaller thrombi produce minimal levels of D-dimer, false negative
Position of Thrombus
Calf vein thrombi, false negative
Sub-segmental PE, false negative
Anticoagulant Therapy
Reduces fibrin formation
D-dimer levels are reduced, false negative
Do Not perform D-dimer on anticoagulated patients
Page 28
© Siemens 2013. All rights reserved.
D-dimer in Hospitalized Patients
Hospitalized patients usually have on-going disease process
D-dimer levels can be elevated in these patients due to disease state
Patients may be tested, but will likely have elevated levels in absence of clot
DO NOT perform D-dimer on hospitalized patients for DVT/PE rule-out
Utilize imaging methods for DVT/PE rule-out
D-dimer is used for DIC in hospitalized patients
Do not use hospitalized patients in a normal reference range study
Page 29
© Siemens 2013. All rights reserved.
Summary for Clinical Utility of D-dimer Assay
Negative D-dimer with low pre-test probability can exclude VTE
D-dimer is cost effective, saving thousands of dollars in health care cost
D-Dimer test results should always be used in conjunction with the patient’s
medical history, pre-test probability scoring and clinical presentation.
Page 30
© Siemens 2013. All rights reserved.
Questions
Page 31
© Siemens 2013. All rights reserved.